IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?

Impact · against what's priced in

The article provides no new fundamental catalysts for the individual large-cap biotech names, as their recent price surges already reflect the industry-wide acquisition thesis and sectoral rotation. While the structural demand for late-stage assets is positive, it is a macro-sector trend already baked into the current valuations of AMGN, GILD, and REGN.

AMGN+0.00

Already priced in

The price assumes

benefiting from the current biotech sector re-rating